Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women

Circulation

Volumn 105, Issue 3, 2002, Pages 304-309

  Brown, Nancy J ^a   Abbas, Amira ^a   Byrne, Daniel ^a   Schoenhard, John A ^a   Vaughan, Douglas E ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiotensin; Hormones; Plasminogen activators

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; CONJUGATED ESTROGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAMIPRIL; RENIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DNA POLYMORPHISM; DRUG CHOICE; DRUG EFFECT; ESTRADIOL BLOOD LEVEL; FEMALE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; POSTMENOPAUSE; RAMIPRIL; RENIN; SINGLE-BLIND METHOD; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0037154329     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc0302.102570     Document Type: Article

References (42)

1. Postmenopausal estrogen therapy and cardiovascular disease: Ten-year follow-up from the nurses' health study
2. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
3. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group
4. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins
5. Acute vascular effects of estrogen in postmenopausal women
6. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women
7. Effects of oral and transdennal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: A randomized controlled trial
8. Haemostatic variables and menopausal status: Influence of hormone replacement therapy
9. Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham population
10. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries
11. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
12. Risk of venous thromboembolism in users of hormone replacement therapy
13. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
14. Prospective study of exogenous hormones and risk of pulmonary embolism in women
15. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
16. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women
17. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study
18. Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women
19. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study Investigators
20. Effect of activation and inhibition of the renin angiotensin system on plasma PAI-1 in humans
21. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction
22. Allele specific increase in basal transcription of the plasminogen activator inhibitor-I gene is associated with myocardial infarction
23. Reassessment of plasma angiotensin measurement: Effects of protease inhibitors and sample handling procedures
24. Increased expression of angiotensin peptides in the brain of transgenic hypertensive rats
25. Angiotensin-(1-7) and nitric oxide interaction in renovascular hypertension
26. Interactive effect of PAI-1 4G/5G genotype and salt intake on PAI-1 antigen
27. Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women
28. Differential effects of enalapril and nitrendipine on the fibrinolytic system in essential hypertension
29. Hormone replacement therapy increases plasma level of angiotensin II in postmenopausal hypertensive women
30. Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women
31. Antihypertensive effect of the oral angiotensin converting enzyme inhibitor SQ 14225 in man
32. Aldosterone escape during ACE inhibitor therapy in chronic heart failure
33. Oral, but not transdermal, administration of estrogens lowers tissue-type plasminogen activator levels in humans without affecting endothelial synthesis
34. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells
35. Angiotensin II stimulation of plasminogen activator inhibitor-1 gene expression in astroglial cells from the brain
36. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells
37. Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells
38. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production
39. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects
40. Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis
41. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells
42. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease